These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 657151

  • 1. Influence of continuous infusion of cytosine arabinoside on sequencing with daunorubicin in L1210 leukemia.
    Edelstein M, Valeriote F, Vietti T.
    Cancer Treat Rep; 1978 Apr; 62(4):547-8. PubMed ID: 657151
    [No Abstract] [Full Text] [Related]

  • 2. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Edelstein M, Vietti T, Valeriote F.
    Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905
    [No Abstract] [Full Text] [Related]

  • 3. Use of cell-cycle information in the preparation of drug combinations: results with cytosine arabinoside plus actinomycin D1,2.
    Bhuyan BK, Fraser TJ, Day KJ.
    Cancer Treat Rep; 1976 Dec; 60(12):1813-8. PubMed ID: 1036090
    [Abstract] [Full Text] [Related]

  • 4. Cytotoxic effects of the lysosomotropic agents DNA-ellipticine, DNA-daunorubicin, and DNA-ellipticine:daunorubicin on L1210 leukemia cells.
    Sorace RA, Sheid B.
    Cancer Treat Rep; 1979 Jan; 63(1):43-51. PubMed ID: 421232
    [No Abstract] [Full Text] [Related]

  • 5. Resting cells in L1210 and JB-1 ascites tumors with special emphasis on recycling.
    Hartmann NR, Dombernowsky P, Bichel P.
    Cancer Treat Rep; 1976 Dec; 60(12):1861-70. PubMed ID: 1026340
    [No Abstract] [Full Text] [Related]

  • 6. In vivo synchrony of solid B16 melanoma by cytosine arabinoside, an inhibitor of DNA synthesis.
    Gibson MH, Bertalanffy FD.
    J Natl Cancer Inst; 1972 Oct; 49(4):1007-18. PubMed ID: 5084119
    [No Abstract] [Full Text] [Related]

  • 7. Synchronization of L1210 leukemia with hydroxyurea infusion and the effect of subsequent pulse dose chemotherapy.
    Moran RE, Straus MJ.
    Cancer Treat Rep; 1980 Jan; 64(1):81-6. PubMed ID: 7379059
    [Abstract] [Full Text] [Related]

  • 8. Morphologic differences in leukemic cells (L1210) exposed to 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Iwasaki H, Aoyama H, Ueda T, Uchida M, Nakamura T.
    Anticancer Res; 1992 Jan; 12(3):941-7. PubMed ID: 1622152
    [Abstract] [Full Text] [Related]

  • 9. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
    Avery TL, Roberts D.
    Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479
    [No Abstract] [Full Text] [Related]

  • 10. Combined effect of cytosine arabinoside and thiopurines.
    Valeriote F, Vietti T, Edelstein M.
    Cancer Treat Rep; 1976 Dec; 60(12):1925-34. PubMed ID: 1026347
    [Abstract] [Full Text] [Related]

  • 11. Quantitative description of morphologic changes effected by antileukemic agents in L1210 leukemia cells.
    Iwasaki H, Liu YP, Nojyo Y, Ueda T, Nakamura T.
    Anticancer Res; 1995 Dec; 15(1):133-9. PubMed ID: 7733623
    [Abstract] [Full Text] [Related]

  • 12. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
    Malpas J, Mathé G, Hayat M.
    Bull Cancer; 1974 Dec; 61(3):411-8. PubMed ID: 4533741
    [No Abstract] [Full Text] [Related]

  • 13. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
    Burke PJ, Karp JE, Vaughan WP.
    J Natl Cancer Inst; 1981 Sep; 67(3):529-38. PubMed ID: 6944525
    [Abstract] [Full Text] [Related]

  • 14. Cytokinetic analysis of L1210 leukemia after continuous infusion of hydroxyurea in vivo.
    Moran RE, Straus MJ.
    Cancer Res; 1979 May; 39(5):1616-22. PubMed ID: 427801
    [No Abstract] [Full Text] [Related]

  • 15. Isolation and characterization of subclones of L1210 murine leukemia with different sensitivities to various cytotoxic agents.
    Brouwer M, Smets LA, Jongsma AP.
    Cancer Res; 1983 Jun; 43(6):2884-8. PubMed ID: 6850600
    [Abstract] [Full Text] [Related]

  • 16. Computer simulation of leukemia therapy: combined pharmacokinetics, intracellular enzyme kinetics, and cell kinetics of the treatment of L1210 leukemia by cytosine arabinoside.
    Lincoln T, Morrison P, Aroesty J, Carter G.
    Cancer Treat Rep; 1976 Dec; 60(12):1723-39. PubMed ID: 1026330
    [Abstract] [Full Text] [Related]

  • 17. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
    Takahashi I, Hara M, Ohmoto E, Oda Y, Endo Y, Fujimoto S, Uchida K, Takaoka K, Watanabe S, Lai M, Kohi F, Kitajima K, Kimura I, Sanada H, Tokioka M, Adachi T, Yorimitsu S.
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
    [Abstract] [Full Text] [Related]

  • 18. Effects of methotrexate and cytosine arabinoside on polyamine metabolism in a mouse L1210 leukemia.
    Russell DH.
    Cancer Res; 1972 Nov; 32(11):2459-62. PubMed ID: 5082594
    [No Abstract] [Full Text] [Related]

  • 19. [Treatment of acute myeloblastic leukemia with daunorubicin and cytosine-arabinoside].
    Thorling K, Petersen HS, Jensen KB, Bastrup-Madsen P.
    Ugeskr Laeger; 1972 Oct 16; 134(42):2201-5. PubMed ID: 4507751
    [No Abstract] [Full Text] [Related]

  • 20. Detection of cytosine arabinoside resistant cells at low frequency using the bromodeoxyuridine/DNA assay.
    Waldman FM, Dolbeare F, Gray JW.
    Cytometry; 1985 Nov 16; 6(6):657-62. PubMed ID: 4064845
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.